Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Non-Current Deffered Revenue (2016 - 2023)

Historic Non-Current Deffered Revenue for Cartesian Therapeutics (RNAC) over the last 9 years, with Q4 2023 value amounting to $3.5 million.

  • Cartesian Therapeutics' Non-Current Deffered Revenue changed N/A to $3.5 million in Q4 2023 from the same period last year, while for Dec 2023 it was $3.5 million, marking a year-over-year change of. This contributed to the annual value of $3.5 million for FY2023, which is N/A changed from last year.
  • Cartesian Therapeutics' Non-Current Deffered Revenue amounted to $3.5 million in Q4 2023.
  • In the past 5 years, Cartesian Therapeutics' Non-Current Deffered Revenue ranged from a high of $51.5 million in Q3 2020 and a low of $3.5 million during Q4 2023
  • For the 5-year period, Cartesian Therapeutics' Non-Current Deffered Revenue averaged around $16.3 million, with its median value being $14.7 million (2020).
  • Per our database at Business Quant, Cartesian Therapeutics' Non-Current Deffered Revenue skyrocketed by 1061007.75% in 2019 and then tumbled by 7289.72% in 2022.
  • Over the past 5 years, Cartesian Therapeutics' Non-Current Deffered Revenue (Quarter) stood at $14.7 million in 2019, then surged by 163.94% to $38.7 million in 2020, then crashed by 70.53% to $11.4 million in 2021, then crashed by 52.39% to $5.4 million in 2022, then tumbled by 34.92% to $3.5 million in 2023.
  • Its last three reported values are $3.5 million in Q4 2023, $4.0 million for Q3 2023, and $4.9 million during Q2 2023.